|
Compound class:
Antibody
Comment: IMAB362 is an investigational, first-in-class monoclonal antibody targeting the cell surface molecule claudin18.2 (CLDN18.2), a pan-cancer drug target [1]. Claudin-18 is a tight-junction protein. Splice variant 2 is reported to be a highly selective cell lineage marker of gastric mucosal cells. CLDN18.2 is retained on malignant transformation and is expressed in a significant proportion of primary gastric cancers and their metastases, and ectopic expression of CLDN18.2 is identified in distinct histologic subtypes of pancreatic (primary tumour and metastases) [2], esophageal, ovarian, and lung tumours [1]. The antibody binds to the first extracellular N-terminal domain which is unique to the CLDN18.2 splice variant [1-2].
|
| No information available. |
Summary of Clinical Use  |
| IMAB362 is being evaluated in Phase 2 clinical trials for advanced gastroesophageal cancer (as monotherapy in NCT01197885) and in combination with the EOX regimen (epirubicin, oxaliplatin and capecitabine) in claudin18.2-positive gastric cancers (NCT01630083). |
| Mechanism Of Action and Pharmacodynamic Effects |
| IMAB362 inhibits tumour growth and kills cancer cells by indirect (complement-dependent cytotoxicity, antibody-dependent cellular cytotoxicity) and direct (antiproliferative and proapoptotic) mechanisms. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT01197885 | Efficacy and Safety Study of Multiple Doses of IMAB362 in Patients With Advanced Gastroesophageal Cancer | Phase 2 Interventional | Astellas Pharma Inc | ||
| NCT01630083 | Efficacy and Safety of IMAB362 in Combination With the EOX Regimen for CLDN18.2-positive Gastric Cancer | Phase 2 Interventional | Astellas Pharma Inc | ||
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License
